These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29653859)

  • 1. Chemodenervation for the Treatment of Facial Dystonia: A Report by the American Academy of Ophthalmology.
    Bilyk JR; Yen MT; Bradley EA; Wladis EJ; Mawn LA
    Ophthalmology; 2018 Sep; 125(9):1459-1467. PubMed ID: 29653859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm.
    Cannon PS; MacKenzie KR; Cook AE; Leatherbarrow B
    Clin Exp Ophthalmol; 2010 Oct; 38(7):688-91. PubMed ID: 20456439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin injections for the treatment of hemifacial spasm over 16 years.
    Sorgun MH; Yilmaz R; Akin YA; Mercan FN; Akbostanci MC
    J Clin Neurosci; 2015 Aug; 22(8):1319-25. PubMed ID: 26100157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
    Lolekha P; Choolam A; Kulkantrakorn K
    Neurol Sci; 2017 Nov; 38(11):2031-2036. PubMed ID: 28884242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K
    Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
    Ababneh OH; Cetinkaya A; Kulwin DR
    Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of flexible onabotulinum toxin A treatment in facial dystonia.
    Bladen JC; Feldman I; Favor M; Dizon M; Litwin A; Malhotra R
    Eye (Lond); 2019 Mar; 33(3):349-352. PubMed ID: 30202071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
    Badarny S; Susel Z; Honigman S
    Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique.
    Saad J; Gourdeau A
    J Neuroophthalmol; 2014 Sep; 34(3):233-6. PubMed ID: 24739994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm.
    Bentivoglio AR; Fasano A; Ialongo T; Soleti F; Lo Fermo S; Albanese A
    Eur J Neurol; 2009 Mar; 16(3):392-8. PubMed ID: 19364366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two different formulations of botulinum toxin A for the treatment of blepharospasm and hemifacial spasm.
    Wu CJ; Shen JH; Chen Y; Lian YJ
    Turk Neurosurg; 2011; 21(4):625-9. PubMed ID: 22194126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of Tolerance and Safety Profiles of Long-Term Botulinum Neurotoxin Type A in Asian Patients with Hemifacial Spasm and Benign Essential Blepharospasm.
    Lai KKH; Tsang A; Kuk AKT; Ko CKL; Chan E; Ko STC
    Neuroophthalmology; 2021; 45(5):293-300. PubMed ID: 34566211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1.
    Sampaio C; Ferreira JJ; Simões F; Rosas MJ; Magalhães M; Correia AP; Bastos-Lima A; Martins R; Castro-Caldas A
    Mov Disord; 1997 Nov; 12(6):1013-8. PubMed ID: 9399229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facial dystonias and rosacea: is there an association?
    Khan TT; Donaldson J; Hesse RJ
    Orbit; 2014 Aug; 33(4):276-9. PubMed ID: 24831933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of Botulinum Toxins for Aesthetic Uses.
    Gart MS; Gutowski KA
    Clin Plast Surg; 2016 Jul; 43(3):459-71. PubMed ID: 27363760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm.
    Chundury RV; Couch SM; Holds JB
    Ophthalmic Plast Reconstr Surg; 2013; 29(3):205-7. PubMed ID: 23552607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benign essential blepharospasm: risk factors with reference to hemifacial spasm.
    Hall TA; McGwin G; Searcey K; Xie A; Hupp SL; Owsley C; Kline LB
    J Neuroophthalmol; 2005 Dec; 25(4):280-5. PubMed ID: 16340493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
    Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
    Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Grey Matter Microstructural Integrity Alterations in Blepharospasm Are Partially Reversed by Botulinum Neurotoxin Therapy.
    Alexandru H; Muthuraman M; Chirumamilla VC; Koirala N; Paktas B; Deuschl G; Zeuner KE; Groppa S
    PLoS One; 2016; 11(12):e0168652. PubMed ID: 27992533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
    Pagan FL; Harrison A
    Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.